Jefferies raised the firm’s price target on Eli Lilly to $310 from $290 and keeps a Hold rating on the shares after the company presented interim data from remternetug’s Phase 1 trial at the ADPD meeting. While amyloid clearance seems to be faster compared to donanemab, it is unclear how this translates to clinical efficacy, said the firm, which adds that it remains "mixed" in its view of Lilly’s Alzheimer’s drugs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Lilly reports Alzheimer’s treatment reduced amyloid in small study, Reuters says
- Viking Therapeutics price target raised to $31 from $20 at BTIG
- ‘Our Best Long-Term Picks’: Morgan Stanley Suggests 3 High-Quality Stocks to Buy Now
- Stifel argues sympathy trading not a predictor for Viking’s pending VK2735 data
- Roche to collaborate with Lilly on early diagnosis of Alzheimer’s disease